Clinical Trials Logo

Malignant Melanoma clinical trials

View clinical trials related to Malignant Melanoma.

Filter by:

NCT ID: NCT00235482 Completed - Malignant Melanoma Clinical Trials

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

PXS-X02
Start date: November 8, 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.

NCT ID: NCT00232726 Completed - Neoplasm Metastasis Clinical Trials

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.

NCT ID: NCT00204607 Completed - Malignant Melanoma Clinical Trials

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Start date: July 2004
Phase: Phase 1/Phase 2
Study type: Interventional

vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen

NCT ID: NCT00204594 Completed - Malignant Melanoma Clinical Trials

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis.

NCT ID: NCT00204516 Completed - Malignant Melanoma Clinical Trials

Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

Start date: April 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen.

NCT ID: NCT00203008 Completed - Parkinson's Disease Clinical Trials

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Start date: January 2003
Phase: N/A
Study type: Observational

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

NCT ID: NCT00179764 Completed - Malignant Melanoma Clinical Trials

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

Start date: March 10, 2000
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness of transplantation of high doses of peripheral blood stem cells (stem cells are special cells found in the blood and bone marrow that produce new blood cells) after treatment with non-myeloablative chemotherapy (not toxic to the bone marrow). In addition, this study will assess the side effects of the transplant.

NCT ID: NCT00179608 Completed - Malignant Melanoma Clinical Trials

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Start date: September 1, 2005
Phase: Phase 1
Study type: Interventional

This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy. This study will evaluate the safety and preliminary efficacy of the combination of lenalidomide and DTIC. Subjects will be receive lenalidomide for 14 consecutive days and DTIC on day one of each 21 day cycle.

NCT ID: NCT00145158 Terminated - Malignant Melanoma Clinical Trials

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Start date: January 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document the tumor response in patients receiving the vaccines.

NCT ID: NCT00145145 Terminated - Malignant Melanoma Clinical Trials

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Start date: January 12, 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purposes of this study are to determine whether immunization with the MAGE-3.A1 peptide mixed with CpG 7909 results in a detectable immune response; to determine the safety of this vaccine and to document the tumor response to the vaccine.